Price
$10.17
Decreased by -0.10%
Dollar volume (20D)
24.76 M
ADR%
5.36
Shares float
22.21 M
Shares short
2.74 M [12.35%]
Shares outstanding
38.27 M
Market cap
389.63 M
Beta
1.51
Price/earnings
N/A
20D range
6.59 11.35
50D range
4.80 11.35
200D range
4.80 18.13

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.

The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity.

Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2.

Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 8, 25 -0.80
Increased by +25.23%
-0.90
Increased by +11.46%
Mar 4, 25 -1.03
Decreased by -21.18%
-1.02
Decreased by -0.82%
Nov 5, 24 -1.05
Decreased by -16.83%
-0.89
Decreased by -18.15%
Aug 8, 24 -0.18
Increased by +81.25%
-1.04
Increased by +82.69%
May 10, 24 -1.07
Decreased by -143.18%
-1.26
Increased by +15.08%
Mar 6, 24 -0.85
Decreased by -251.79%
-1.03
Increased by +17.48%
Nov 7, 23 -0.90
Decreased by -3.10 K%
-1.20
Increased by +25.00%
Aug 8, 23 -0.96
Decreased by -740.00%
-1.03
Increased by +6.80%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 0.00
Decreased by N/A%
-34.61 M
Increased by +9.43%
Decreased by N/A%
Decreased by N/A%
Dec 31, 24 0.00
Increased by +100.00%
-43.71 M
Decreased by -43.08%
Decreased by N/A%
Decreased by N/A%
Sep 30, 24 0.00
Decreased by N/A%
-45.36 M
Decreased by -40.68%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 35.00 M
Increased by +N/A%
-7.13 M
Increased by +79.22%
Decreased by -20.37%
Decreased by N/A%
Mar 31, 24 0.00
Decreased by -100.00%
-38.22 M
Decreased by -145.75%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 -11.30 M
Decreased by -120.97%
-30.55 M
Decreased by -249.37%
Increased by +270.29%
Increased by +612.37%
Sep 30, 23 0.00
Decreased by -100.00%
-32.24 M
Decreased by -3.35 K%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by -100.00%
-34.30 M
Decreased by -709.67%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY